Zhou Li, Guo Sheng-Nan, Gao Ying
Department of Neurology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing, 100700, China.
Curr Vasc Pharmacol. 2015;13(4):475-91. doi: 10.2174/1570161112666141014150232.
Stroke is a disease with high morbidity, disability, and fatality. Since ischemic stroke is the most common kind of stroke, increasing attention has been paid to its prevention and treatment. Given the limitations of conventional medicine, there is growing interest in Chinese Medicine (CM), especially Chinese Patent Medicine (CPM) for its convenience and stability. Studies of CM show that Chinese Patent Medicines for Tonifying Qi and Promoting Blood Circulation (CPMs-TQPBC) are one of the most common and effective categories of all clinical CPMs in China.
This review investigated and summarized the randomized controlled trials (RCT) of CPMs-TQPBC combined with conventional interventions in the last 10 years.
Trial results demonstrated the potential in reducing the endpoints and improving neurologic impairments, body movements, Barthel index, quality of life, and certain biomarkers. Furthermore, certain CM syndromes were alleviated with rare adverse events. Advantages of interventions combined with CPMs-TQPBC for patients with cerebral infarction were discovered. Compared with the Chinese patent medicines for promoting blood circulation (CPMs-PBC) alone, CPMs for both tonifying qi and promoting blood circulation exhibited noticeably better effects. The underlying reasons could be related to the improvement of microcirculation in the brain, protection against ischemic reperfusion injury, generation of neuroprotective factors, and inhibition of apoptosis.
Under the circumstances of qi deficiency and blood stasis syndrome (QDBSS) (Qixu-Xueyu Zheng), CPMs- TQPBC showed a substantial difference. More trials focusing on specific patient groups should be carried out to corroborate and expand the findings.
中风是一种发病率、致残率和死亡率都很高的疾病。由于缺血性中风是最常见的中风类型，其预防和治疗受到了越来越多的关注。鉴于传统医学的局限性，人们对中医药，尤其是中成药的便利性和稳定性越来越感兴趣。中医药研究表明，益气活血类中成药是中国所有临床中成药中最常见、最有效的类别之一。
本综述调查并总结了过去10年中益气活血类中成药联合传统干预措施的随机对照试验（RCT）。
试验结果表明，益气活血类中成药在降低终点事件、改善神经功能缺损、肢体运动、Barthel指数、生活质量和某些生物标志物方面具有潜力。此外，某些中医证候得到缓解，不良事件罕见。发现了益气活血类中成药联合干预对脑梗死患者的优势。与单纯活血化瘀类中成药相比，益气活血类中成药的效果明显更好。其潜在原因可能与改善脑微循环、保护缺血再灌注损伤、产生神经保护因子和抑制细胞凋亡有关。
在气虚血瘀证的情况下，益气活血类中成药表现出显著差异。应开展更多针对特定患者群体的试验，以证实和扩展这些发现。
